D&D Pharmatech Inc.
D&D Pharmatech is a KOSDAQ-listed (347850) developer based in Seongnam, South Korea, focused on liver and metabolic disease. Its candidate zabopegdutide (DD01) is in a US Phase 2 study in MASH, with 48-week histology results reported in May 2026.
| Headquarters | Seongnam, South Korea |
|---|---|
| Listing | KOSDAQ:347850 |
| Lead asset / stage | zabopegdutide (DD01) Phase 2 — United States (MASH) |
| Latest event | D&D Pharmatech announced 48-week histology results for zabopegdutide in MASH. |